FOLFOX4 or XELOX

Phase 3Small molecule

FFederation Francophone de Cancerologie Digestive

FOLFOX4 or XELOX is one of 53 small molecule programs targeting Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaRecruiting

AdenocarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

100 competitors in Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

43 2

Gemzar

Johnson & Johnson

Phase 3

16 3

Taxol

Teva

Phase 3

14 4

Keytruda

Merck & Co.

Phase 3

14 5

Taxotere

AAvyxa

Phase 3

19 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

17 7

Beyfortus

BeiGene

Phase 3

4 8

Opdivo

Bristol-Myers Squibb

Phase 3

3 9

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

11 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adenocarcinoma1 trial

Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT02355379·774 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FOLFOX4 or XELOX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOX4 or XELOX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOX4 or XELOX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federation Francophone de Cancerologie Digestive company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFederation Francophone de Cancerologie Digestive

FOLFOX4 or XELOX

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News